Despite the fact that Zentalis Pharmaceuticals, Inc.'s (NASDAQ:ZNTL) value has dropped 17% in the last week insiders who sold US$117k worth of stock in the past 12 months have had less success. Insiders would probably have been better off holding on to their shares given that the average selling price of US$2.43 is still lower than the current share price.
Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing.
In the last twelve months, the biggest single sale by an insider was when the SVP of Finance & Principal Accounting Officer, Vincent Vultaggio, sold US$73k worth of shares at a price of US$2.43 per share. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. It's of some comfort that this sale was conducted at a price well above the current share price, which is US$1.49. So it is hard to draw any strong conclusion from it.
In the last year Zentalis Pharmaceuticals insiders didn't buy any company stock. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
Check out our latest analysis for Zentalis Pharmaceuticals
I will like Zentalis Pharmaceuticals better if I see some big insider buys. While we wait, check out this free list of undervalued and small cap stocks with considerable, recent, insider buying.
I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. We usually like to see fairly high levels of insider ownership. From looking at our data, insiders own US$3.2m worth of Zentalis Pharmaceuticals stock, about 2.0% of the company. We do note, however, it is possible insiders have an indirect interest through a private company or other corporate structure. We prefer to see high levels of insider ownership.
It doesn't really mean much that no insider has traded Zentalis Pharmaceuticals shares in the last quarter. We don't take much encouragement from the transactions by Zentalis Pharmaceuticals insiders. We also note that, as far as we can see, insider ownership is fairly low, compared to other companies. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. For instance, we've identified 3 warning signs for Zentalis Pharmaceuticals (2 are a bit concerning) you should be aware of.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.